InvestorsHub Logo
Followers 85
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: biopharm post# 171045

Thursday, 04/17/2014 3:24:37 PM

Thursday, April 17, 2014 3:24:37 PM

Post# of 346375
Dr. Rolf Brekken : Peregrine Pharmaceuticals KOL :


Applicants Eligible for Continuous Submission.
-Updated April 10, 2014

Brekken, Rolf A-8/16/2017

https://grants.nih.gov/grants/peer/CS_2013_combined.pdf


"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News